Order Article Reprints

Kim JH, Yoo C, Seo S, Jeong JH, Ryoo B-Y, Kim K-p, Lee JB, Lee K-W, Kim J-W, Kim I-H, et al. A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY. Cancers. 2022; 14(3):559. https://doi.org/10.3390/cancers14030559

Kim, Jwa Hoon, Changhoon Yoo, Seyoung Seo, Jae Ho Jeong, Baek-Yeol Ryoo, Kyu-pyo Kim, Jung Bok Lee, Keun-Wook Lee, Ji-Won Kim, Il-Hwan Kim, and et al. 2022. "A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY" Cancers 14, no. 3: 559. https://doi.org/10.3390/cancers14030559

Kim, J. H., Yoo, C., Seo, S., Jeong, J. H., Ryoo, B.-Y., Kim, K.-p., Lee, J. B., Lee, K.-W., Kim, J.-W., Kim, I.-H., Kang, M., Ryu, H., Cheon, J., & Park, S. R. (2022). A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY. Cancers, 14(3), 559. https://doi.org/10.3390/cancers14030559